BRAF and skin neoplasm: In several clinical studies, cotargeting of BRAF together with MEK significantly delays secondary resistance, with a longer mPFS than with BRAF inhibitor monotherapy, as well as prevents formation of secondary skin tumors [19, 99, 100].